GFAP and Alzheimer disease: To compensate for this shortcoming, we analyzed serum SV2A in combination with serum GFAP, a biomarker with high specificity, and the serial test results showed that the specificity of this diagnostic model for populations at risk of AD significantly increased to 91.7%.